These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 20563672)

  • 1. Mineralocorticoid receptor antagonists and the metabolic syndrome.
    Tirosh A; Garg R; Adler GK
    Curr Hypertens Rep; 2010 Aug; 12(4):252-7. PubMed ID: 20563672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aldosterone: role in the cardiometabolic syndrome and resistant hypertension.
    Whaley-Connell A; Johnson MS; Sowers JR
    Prog Cardiovasc Dis; 2010; 52(5):401-9. PubMed ID: 20226958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of mineralocorticoid receptor in insulin resistance.
    Garg R; Adler GK
    Curr Opin Endocrinol Diabetes Obes; 2012 Jun; 19(3):168-75. PubMed ID: 22499218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure.
    George J; Struthers AD
    Expert Opin Pharmacother; 2007 Dec; 8(17):3053-9. PubMed ID: 18001264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone.
    Hu X; Li S; McMahon EG; Lala DS; Rudolph AE
    Mini Rev Med Chem; 2005 Aug; 5(8):709-18. PubMed ID: 16101407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists.
    Yugar-Toledo JC; Modolo R; de Faria AP; Moreno H
    Vasc Health Risk Manag; 2017; 13():403-411. PubMed ID: 29081661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension.
    Sowers JR; Whaley-Connell A; Epstein M
    Ann Intern Med; 2009 Jun; 150(11):776-83. PubMed ID: 19487712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
    Moore TD; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension.
    Sato A; Fukuda S
    J Hum Hypertens; 2010 Jun; 24(6):387-94. PubMed ID: 19865106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aldosterone antagonism: an emerging strategy for effective blood pressure lowering.
    Pratt-Ubunama MN; Nishizaka MK; Calhoun DA
    Curr Hypertens Rep; 2005 Jun; 7(3):186-92. PubMed ID: 15913492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mineralocorticoid receptor antagonists and hypertension: is there a rationale?
    Gumieniak O; Williams GH
    Curr Hypertens Rep; 2004 Aug; 6(4):279-87. PubMed ID: 15257862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypertension, angiotensin II, aldosterone, and race.
    Ben-Yehuda O
    J Am Coll Cardiol; 2003 Apr; 41(7):1156-8. PubMed ID: 12679216
    [No Abstract]   [Full Text] [Related]  

  • 13. The promise of selective aldosterone receptor antagonists for the treatment of hypertension and congestive heart failure.
    Hameedi A; Chadow HL
    Curr Hypertens Rep; 2000 Aug; 2(4):378-83. PubMed ID: 10981173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aldosterone, mineralocorticoid receptor and the metabolic syndrome: role of the mineralocorticoid receptor antagonists.
    Ronconi V; Turchi F; Appolloni G; di Tizio V; Boscaro M; Giacchetti G
    Curr Vasc Pharmacol; 2012 Mar; 10(2):238-46. PubMed ID: 22022770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eplerenone restores 24-h blood pressure circadian rhythm and reduces advanced glycation end-products in rhesus macaques with spontaneous hypertensive metabolic syndrome.
    Zhang Y; Zheng W; Liu Y; Wang J; Peng Y; Shang H; Hou N; Hu X; Ding Y; Xiao Y; Wang C; Zeng F; Mao J; Zhang J; Ma D; Sun X; Li C; Xiao RP; Zhang X
    Sci Rep; 2016 Apr; 6():23957. PubMed ID: 27032687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eplerenone: a review of its use in essential hypertension.
    Croom KF; Perry CM
    Am J Cardiovasc Drugs; 2005; 5(1):51-69. PubMed ID: 15631538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of aldosterone receptor blockers in the treatment of hypertension.
    Weinberger MH
    J Clin Hypertens (Greenwich); 2004 Nov; 6(11):632-5. PubMed ID: 15538096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eplerenone potentiates protective effects of amlodipine against cardiovascular injury in salt-sensitive hypertensive rats.
    Nakamura T; Fukuda M; Kataoka K; Nako H; Tokutomi Y; Dong YF; Yamamoto E; Yasuda O; Ogawa H; Kim-Mitsuyama S
    Hypertens Res; 2011 Jul; 34(7):817-24. PubMed ID: 21471977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mineralocorticoid receptor antagonists and endothelial function.
    Maron BA; Leopold JA
    Curr Opin Investig Drugs; 2008 Sep; 9(9):963-9. PubMed ID: 18729003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Selective Mineralocorticoid Receptor Blockade on Flow-Mediated Dilation and Insulin Resistance in Older Adults with Metabolic Syndrome.
    Hwang MH; Yoo JK; Luttrell M; Meade TH; English M; Christou DD
    Metab Syndr Relat Disord; 2015 Oct; 13(8):356-61. PubMed ID: 26302093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.